Description

The Center for Epilepsy Drug Discovery (CEDD) at the University of Washington provides a path for the evaluation of promising investigational compounds in strategically selected and mechanistically relevant preclinical seizure and epilepsy models. Knowledge gained will assist advancement of analogue compounds, inform clinical trial design for the most promising investigational compounds, identify adverse effects liability, and minimize costs associated with the early evaluation of compounds in etiologically relevant animal models neuronal hyperexcitability and associated comorbidities.

Partners

UW Departments of Pharmacy and Pharmaceutics, UW School of Pharmacy; Departments of Neurology and Neurosurgery, UW School of Medicine; UW Department of Veterinary Medicine; UW Department of Comparative Medicine; UW School of Pharmacy Comparative Health Outcomes, Policy and Economics (CHOICE) Institute; UW School of Pharmacy Plein Center for Geriatric Pharmacy Research, Education and Outreach: UW School of Pharmacy MS in Biomedical Regulatory Affairs (BRAMS Program); UW Center on Human Development and Disability (CHDD), UW Center for Cannabis Research (CCR); UW Center for Exposures, Diseases, Genomics, and Environment (EDGE); UW Addictions, Drug & Alcohol Institute.

University of Utah Anticonvulsant Drug Development Program, Hebrew University of Jerusalem, UCB Pharma

Funders

National Institute of Neurological Disorders and Stroke, National Institute of Aging, American Epilepsy Society, Washington Research Foundation, and pharmaceutical industry-sponsored research.